The World Child Cancer (WCC) organisation has held its half-year review meeting of 2025 with stakeholders of its Haematology ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Envestnet Asset Management significantly raised its holdings in Amgen, reflecting growing confidence in the biotech giant.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Ultragenyx Pharmaceutical Inc. shares plunged 30% as UX143 trial raises efficacy doubts. Click for more on RARE and my ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.